Story
Editas Medicine Stock Surges on Guggenheim Upgrade to Buy
Shares of Editas Medicine (NASDAQ: EDIT) surged more than 7% in pre-market trading on September 23 after investment firm Guggenheim upgraded the stock to Buy from a previous Neutral rating.
The firm also initiated a $5.00 price target on the clinical-stage biotechnology company, signaling significant potential upside from its pre-market price of $3.13.
Upgrade Driven by Cholesterol Drug Potential
Guggenheim's bullish thesis is centered on EDIT-401, Editas' lead in vivo gene editing therapy designed to treat severe hypercholesterolemia. The analyst note highlighted the therapy's strong preclinical data, which underpins the firm's updated financial models for the program.
Key preclinical findings for EDIT-401 include:
- Reductions in LDL-C (low-density lipoprotein cholesterol) of more than 90%.
- Reductions in Apolipoprotein B (ApoB) of more than 70%.
AdThe therapy uses a dual-gRNA approach to upregulate LDLR expression. Guggenheim sees potential for EDIT-401 to address a significant niche market of patients with atherosclerotic cardiovascular disease who require substantial cholesterol reduction.
Near-Term Catalyst and Market Context
The upgrade comes ahead of a key clinical inflection point for Editas. The company plans to begin a Phase 1/2a clinical study for EDIT-401 in the fourth quarter of 2026. While Guggenheim acknowledged that questions remain regarding the safety and potential off-target effects of the therapy's dual double-strand break strategy, it views the risk-reward profile as favorable.
The stock's advance was a company-specific event, standing in contrast to the broader market, where major indices like the S&P 500 and NASDAQ were trading modestly lower in the pre-market session. The rally underscores investor optimism surrounding the upcoming clinical trial and the new analyst endorsement.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.